

Identification and Characterization of a Single-Center Cohort of Patients With **Refractory or Relapsing Immune Checkpoint Inhibitor-Induced Colitis**

INTRODUCTION

Immune checkpoint inhibitors (ICIs) are the latest development in the fight against cancer. ICI-induced colitis is seen frequently, in 8.7% to 54% of individuals undergoing ICI therapy.¹⁻²

The pathogenesis of ICI-colitis appears to arise from increased CD8+ tissue resident T cells activation in colonic mucosa, which is distinct from the immunological changes seen in traditional inflammatory bowel disease.³⁻⁴

Treatment for ICI-induced toxicities relies on immunosuppressants such as corticosteroids and biologic therapy. These treatments are not always sufficient, and recent meta-analysis found that corticosteroids were only effective in 59% of cases.5

We sought to characterize and describe the disease and treatment course of those individuals who suffer prolonged courses of ICI colitis. Predicting which patients are susceptible to either a second episode of colitis or refractory colitis would allow providers to better tailor colitis-directed treatment, resume ICI therapy sooner, and ultimately reduce cancer mortality.

MATERIAL AND METHODS

Retrospective chart review was performed across a multisite health system. To identify cases of ICI-induced colitis we utilized the hospital system's Unified Data Platform. Cases were identified for medication administrations of FDA-approved immune checkpoint inhibitors prior to December 1st 2021. Cases were then narrowed based on UDP search of clinical notation identifying "colitis."

Clinical documentation was abstracted to determine the duration of ICI therapy, duration of symptoms, diagnostic evaluation, and treatment course. Colitis was defined clinically based on CTCAE V5 criteria for colitis.⁶

Cases were subdivided into four different groups. "Responsive" cases were those with a single episode of colitis that responded to treatment without relapse or recurrence. "Refractory" cases were those with no symptom improvement after more than 30 days of definitive treatment but with eventual symptom resolution. "Second colitis" cases had complete resolution of their symptoms but then proceeded to develop a second de novo episode of colitis. <u>"Unresolved</u>" cases never had symptom resolution at the time of last follow up.


Data was abstracted and imported into Bluesky statistical software. The statistical analysis utilized BlueSky Statistics software v. 7.10 (BlueSky Statistics LLC, Chicago, IL, USA). Categorical variables across different groups were analyzed by Chi-Squared analysis, and numerical variables were analyzed by ANOVA in BlueSky. To evaluate for predictive factors for refractory recurrent colitis logistic regression or cox proportional hazards analysis were performed.

Second Episode of Colitis

Unresolved Symptoms

<u>Thomas W. Fredrick, M.D.¹, Manuel B. Braga Neto, M.D.², Laura E. Raffals, M.D.²</u> ¹Department of Internal Medicine, Mayo Clinic ²Division of Gastroenterology and Hepatology, Mayo Clinic

						RE	SULTS						
Table 1A, Demographics of Patients Developing ICI-induced Colitis						Table 1B Evaluation and Treatment of Colitis					Table 2: Risk Factors for Refractory Colitis (calculate via logistic regression)		
	Single	Single			All Cases		Single	Single	Second	Unresolved	All Cases	Variable	OR (95% CI)
	Episode, Responsive	Episode,	•	f Symptoms N=15	n=148		Episode,	Episode,	•	Symptoms	n=148	Melanoma	0.80 (0.32-1.99)
	Symptoms	Refractory Symptoms		N=15			Responsive Symptoms	Refractory Symptoms	Colitis N=19	N=15		Lung Cancer-NSCLC	0.87 (0.41-1.82)
	N=61	N=53					N=61	N=53	N =15			Prior Chemotherapy	1.31 (0.65-2.63)
												Any Additional Adverse Event	1.48 (0.74-2.98)
Gender f (%)	28 (45.9%)	30 (56 6%)	6 (31.6%)	9 (60 0%)	73 (49.3%)	Colonoscopy obtained	13 (21.3%)	24	3 (15.8%)	4 (26.7%)	44 (29.7%)	Combination of ICI +	1.50 (0.72-3.15)
ge at first ICI median,	66.6 (57.4-	. ,	<u>, т</u>	· · ·	67.4 (57.6-			(45.3%) **		. (_0,0)	(_0,0)	Chemotherapy	
ears (median, IQR)	72.5)	71.7)	71.3)	75.7)	72.4)	Sigmoidoscopy obtained	15 (24.6%)	17 (32.1%)	8 (42 1%)	4 (26 7%)	44 (29.7%)	Multiple ICI Therapy	0.7 (0.32-1.5)
ledian Follow Up After	1.04 (0.46-	1.44 (0.66-	1.93 (0.75-	- 0.22 (0.12-	1.08 (0.46-		10 (24.070)	17 (02.170)	0 (42.170)	+ (20.770)		Number of ICI Doses	1.01 (0.97-1.06)
Symptom Onset, years	1.86)	2.04)	2.69)	0.45)	1.99)	Fecal calprotectin elevated	6 (75.0%)	16 (88.9%)	2 (66.7%)	3 (75.0%)	27 (81.8%)	Pembrolizumab	0.84 (0.41-1.7)
median, IQR)						Treatment						Ipilimumab + Nivolumab	0.7 (0.32-1.5)
Malignancy							40 500 (00	440 (04					
Ielanoma	27 (44.3%)	25 (47.2%)	9 (47.4%)	3 (20.0%)	64 (43.2%)	Duration of symptoms after starting systemic	43.500 (20- 83.8)	119 (61- 192) ***	30 (9-87.8)	NA	65 (22- 118)	Table 3A: Symptoms of Second E	vent of ICI-Colitis
ung Cancer-NSCLC	12 (19.7%)	13 (24.5%)	3 (15.8%)	3 (20.0%)	31 (20.9%)	steroids, days (median,	00.07	,			110)	Immune Checkpoint In	hibitor
0	(/	(, , , , , , , , , , , , , , , , , , ,	()	()		IQR)						Colitis on systemic steroid treatment	5 (26.3%)
Renal cell carcinoma	5 (8.2%)	4 (7.5%)	2 (13.3%)	2 (13.3%)	16 (10.8%)	Systemic Steroids	10 (17.5%)	16 (30.2%)	1 (22 2%)	7 (16 7%)	37 (25.9%)	Colitis on enteral steroid treatment	5 (26.3%)
Other	17 (28%)	11 (21%)	3 (16%)	7 (47%)	37 (25%)	ongoing for colitis †	10 (17.370)	10 (30.2 /0)	4 (22.270)	7 (40.770)	57 (25.970)	Colitis on biologic treatment	1 (5.3%)
Prior Bowel Resection	6 (10.5%)	· · · ·	6 (31.6%) *	(/	19 (13.5%)					101		Time from ICI reintroduction to	59.5 (13.5-154)
	0 (1010 /0)	. (0.070)	• (•• ,•)	0 (2010 / 0)		Duration of budesonide treatment,	138 (70.5- 244.3)	165.5 (107-	137 (119.5- 281)	131 (104.5-	155 (97- 280)	second episode, days (median, IQR)	
						days (median, IQR)	244.07	317.8)	201)	157.5)	2007	CTCAE Grade	
Causative Immune Ch	neckpoint inhi	bitor										1	2 (10.5%)
embrolizumab	27 (44.3%)	21 (39.6%)	8 (42.1%)	7 (46.7%)	63 (42.6%)	Duration of symptoms	42 (14-79)	94 (49.8-	56.5 (21.5-	NA	64.500	2	2 (10.5%)
ivolumab	5 (8.2%)	11 (20.8%)	5 (26.3%)	0 (0.0%)	21 (14.2%)	after starting budesonide, days (median, IQR)		157)	89.8)		(21-134.5)	3	11 (57.9%)
oilimumab + Nivolumab		14 (26.4%)	, ,	\ <i>\</i>	47 (31.8%)							4	2 (10.5%)
Other	5 (8.2%)		3 (15.8%)	2 (13.3%)	17(11.5 %)	Budesonide ongoing	6 (25.0%)	9 (29.0%)	3 (33.3%)	4 (66.7%)	22 (31.4%)	5	2 (10.5%)
CI doses prior to colitis,		6 (3-		6 (3.500-8)	, , , , , , , , , , , , , , , , , , ,	Treatment with biologic	5 (8.2%)	18	2 (10.5%)	2 (13.3%)	27 (18.2%)	Hospitalized	9 (47.4%)
(median, IQR)	, , , ,	10.250)	11)		10.500)			(34.0%) ***				Mortality	2 (10.5%)
Duration of symptoms, days (median, IQR)	59 (24-102)	137 (74-	65 (24.5- 102.5)	80 (43- 163)	80.500 (30.8-	Duration of symptoms after starting biologic	29 (27-62)	68.5 (42- 115.8)	23.5 (13.3- 33.8)	- NA		ICI held due to colitis	18 (100%)
		225) ***										ICI held permanently	12 (66.7%)
					146.5)	Biologic ongoing†	1 (20%)	9 (50%)	2 (66.7%)	2 (100 0%)	14 (50.0%)	Switched to another ICI Treatment	3 (16.7%)
lospitalized for event	30 (49.2%)	26 (49.1%)	9 (47.4%)	12 (80.0%)	77 (52.0%)				. ,	. ,	· · · · · · · · · · · · · · · · · · ·	Systemic Steroids	15 (78.9%)
				*		Suppressive treatment to continue ICI?	9 (25.0%)	19 (63.3%) **	8 (47.1%)	5 (83.3%)	41 (46.1%)	Budesonide	11 (57.9%)
Deceased	25 (41.0%)	15 (28.3%)	7 (36.8%)	13	60 (40.5%)							Biologic	7 (36.8%)
				(86.7%)**									7 (00.070)
ime from event to	332 (168-	332 (141-	521.5	60 (41-	274 (110-							Table 2D. Dials Fractors for Cocord	
eath, days (median,	496)	660.5)	(272.8-	123)	529)	Figure 2: Tre	eatment of C	Colitis by di	sease pres	sentation		Table 3B: Risk Factors for Second	
QR)			612.5)			100.00						Variable	HR (95% CI)
alues given are n, % unless oth	herwise specified					90.00						Melanoma	0.66 (0.26-1.94)
<0.05, ** p< 0.01, *** p<0.001						80.00						NSCLC	0.64 (0.17-2.49)
Ongoing refers to at time of las	st ioliow up					70.00						Prior Chemotherapy	0.13 (0.37-2.38)
— •			-									Prior Radiation	2.50 (1.31-9.36)*
	: CTCAE Gr	ade By Dis	ease Pres	entation		00.00						Combination ICI Plus Chemotherapy	0.48 (0.30-2.08)
						90 20 20 20 20 20 20 20 20 20 20 20 20 20						ICI	
						40.00				-		Pembrolizumab	0.79 (0.57-3.76)
50						30.00						Nivolumab	1.07 (0.20-1.61)
50 SO 40												LETTER I INDU I	4 00 /0 01 10 01
50 01 Gases 40 02 Gases 30												Ipilimumab and Nivolumab	Υ
50 02 Gases 00						20.00						Switched to another ICI	0.59 (0.20-2.39)
50 50 40 30 20 20												Switched to another ICI ICI Doses	0.59 (0.20-2.39) 1.06 (0.91-1.03)
50 50 40 30 20 20 10						20.00 10.00 0.00				rto duubility 10		Switched to another ICI ICI Doses Previous Treatmer	0.59 (0.20-2.39) 1.06 (0.91-1.03) nt
50 50 40 30 20 10 10 0						20.00 10.00 0.00 Treatment with Treatment	atment with idesonide	Treatment with biologic			I restarted while on budesonide	Switched to another ICI ICI Doses	1.69 (0.84-10.21) 0.59 (0.20-2.39) 1.06 (0.91-1.03) nt 0.94 (0.16-1.92) 0.23 (0.45-2.80)



DISCUSSION

- Of 148 cases of ICI-induced colitis, 36% experienced refractory colitis and 13% experienced a second episode of colitis.
- Management of ICI-colitis frequently required systemic and enteral steroids and required holding ICI therapy in 87.2% of cases.
- Regression analysis for risk factors for refractory colitis (table 2) demonstrated the difficulty predicting colitis course.
- Refractory colitis more often required biologic therapy compared to other clinical presentations of colitis.
- Cases experiencing a second episode of colitis trended towards being more likely to have restarted ICI while on enteral or corticosteroids.
- Second episodes of colitis were severe, with 2/19 cases suffering mortality. Prior radiation was the most significant risk factor associated with a second episode of colitis (p=0.01).

CONCLUSIONS

- We describe a comprehensive and complex cohort assessing symptom duration and treatment course of ICIcolitis, with a focus on those developing prolonged or recurrent colitis.
- ICI-induced colitis frequently results in hospitalization and often requires prolonged systemic or enteral steroid courses.
- Predictive factors for individuals who will develop prolonged or recurrent colitis remain to be identified.
- When symptoms remain refractory to systemic and corticosteroids, biologic therapy may be needed to induce clinical improvement.

REFERENCES

- Nice L. Bycroft R. Wu X. et al. Assessment of hospitalization rates for immunerelated adverse events with immune checkpoint inhibitors. J Oncol Pharm Pract 2020:1078155220968909.
- Gupta A, De Felice KM, Loftus EV, Jr., et al. Systematic review: colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther 2015;42:406-17.
- Sasson SC, Slevin SM, Cheung VTF, et al. Interferon-Gamma-Producing CD8(+) Tissue Resident Memory T Cells Are a Targetable Hallmark of Immune Checkpoint
- Inhibitor-Colitis. Gastroenterology 2021;161:1229-1244.e9. Arriola E, Wheater M, Lopez MA, et al. Evaluation of immune infiltration in the colonic mucosa of patients with ipilimumab-related colitis. Oncoimmunology
- 2016:5:e1209615. Ibraheim H, Baillie S, Samaan MA, et al. Systematic review with meta-analysis: effectiveness of anti-inflammatory therapy in immune checkpoint inhibitor-induced enterocolitis. Aliment Pharmacol Ther 2020;52:1432-1452.
- Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. (2017, 04/19/2021).Retrieved from
- https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm